DHX32 is a putative DEAH-box RNA helicase with dual nuclear and mitochondrial localization 1. The protein exhibits widespread tissue expression with cell type-dependent regulation 2 and localizes to mitochondria where it associates with newly synthesized RNA, suggesting involvement in mitochondrial gene expression 1. DHX32 expression is calcium-dependent and regulated by nuclear factor of activated T cells (NF-AT) in T cells 3, where it modulates apoptotic responses by downregulating anti-apoptotic protein c-FLIP short 4. In cancer contexts, DHX32 functions as an oncogene, promoting tumor progression through β-catenin pathway activation. In hepatocellular carcinoma, DHX32 induces epithelial-mesenchymal transition and enhances cell proliferation, migration, and invasion 5. Similarly, in colorectal cancer, overexpressed DHX32 promotes growth, metastasis, and chemotherapy resistance while suppressing pro-apoptotic genes 6. DHX32 also promotes angiogenesis by stabilizing β-catenin and upregulating VEGFA expression, leading to increased microvessel density 7. High DHX32 expression correlates with poor prognosis in multiple cancer types, positioning it as both a potential biomarker and therapeutic target 57.